Supportive care is a high importance area in cancer care and management. Prevention of radiotherapy and chemotherapy induced anemia, management of mucosal injury, treatment of dyspnea, management of cancer pain, venous thromboembolism, bone metastases, cardiovascular toxicity and others hold a critical significance and specific guidelines have been established for delivering best cancer treatment outcomes.

This report titled “Cancer Supportive Care Market - Growth, Future Prospects and Competitive Analysis, 2021 – 2029” is to offer industry investors, company executives, and industry participants with in depth insights to enable them make informed strategic decisions related to the opportunities in the cancer supportive care drugs market. The major target audience of this study include industry investors, cancer drugs manufacturers, distributors, and institutional scholars.

This study classifies the global cancer supportive care market into type therapeutics, cancer types, sales channels and geographical distribution. Based on therapeutic types, the overall market is studied for Oral Mucositis and Dry Mouth, Chemotherapy Induced Nausea and Vomiting, Cancer Pain, Chemotherapy Induced Anemia, Chemotherapy Induced Neutropenia and Bone Metastases. Lung Cancer, Liver Cancer, Breast Cancer, Leukemia, Prostate Cancer, Ovarian Cancer, Bladder Cancer and cancers are the major oncology areas for which the cancer supportive care market is studied. The sales channels considered for distribution of cancer supportive care drugs are hospital pharmacies, retail pharmacies and compounding pharmacies. Market size and forecast for each mentioned segment are provided in this report for the period 2019-2029 (US$ Mn), along with respective CAGR (value %) for the period 2021-2029.

Market size and respective forecast for these regional and country level markets are presented in this study for the period 2019-2029. Market growth rates for the forecast period 2021-2029 are also included in this report, considering 2020 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global cancer supportive care market. Tools such as market positioning of key players, and attractive investment proposition provide the readers with insights on the competitive scenario of the global cancer supportive care market. This report concludes with company profiles section that highlights major information about the key players engaged in development, manufacture and sales of cancer supportive care drugs.

Based on the type cancers where supportive care is significantly in demand, the global cancer supportive care market is segmented as follows:

• Lung Cancer
• Liver Cancer
• Breast Cancer
• Leukemia
• Prostate Cancer
• Ovarian Cancer
• Bladder Cancer
• Others

Among the considered cancer types, where cancer supportive care is observed to be in the highest demand, lung cancer is estimated to be the largest segment. High incidence of lung cancer owing to environmental and lifestyle factors are the chief driving indicators to the dominance of lung cancer segment. Significant growth in incidence of lung cancer in Middle East and Africa and Asia Pacific will further facilitate high demand for lung cancer treatment and supportive care in the regions. In addition incidence of breast and prostate cancer are notably high worldwide. While, simultaneous growth in survival rates indicate impressive success in treatment outcomes and thus supportive care for such cancers.

Based on the type of sales channel, the global cancer supportive care market is segmented as follows:

• Hospital Pharmacies
• Retail Pharmacies
• Compounding pharmacies

Among the considered sales channels, hospitals and clinics capture the largest revenue share in the global cancer supportive care market. However, the geographic distribution of these sales channels considerably vary. This mix majorly varies across countries due to the prevalent healthcare practices, type of formulations used and reimbursement. Distribution of oncology drugs through hospital pharmacies is the highest in European countries such as the U.K., Spain and Italy. Whereas in North America and France, oncology drugs are dominantly distributed through retail pharmacies. Shift towards oral medicines as against injections in targeted therapies majorly contribute to rapid upswing of retail pharmacies in cancer supportive care market.

Based on the therapeutic areas, the global cancer supportive care market is segmented as follows:

• Oral Mucositis and Dry Mouth
• Chemotherapy Induced Nausea and Vomiting
• Cancer Pain
• Chemotherapy Induced Anemia
• Chemotherapy Induced Neutropenia
• Bone Metastases

Supportive care interventions can assist in preventing or minimizing the adverse effects of cancer treatments, across all phases of cancer management. Though associated pain is the largest addressable area in supportive care regimen, chemotherapy induced anemia and chemotherapy induced neutropenia together claim the largest market segment in the overall cancer supportive care market. Drugs such as erythropoietin stimulating agents are largely used for hematological management during cancer treatments. Other therapeutic areas such as chemotherapy induced nausea and vomiting also attract significant focus with several innovative CINV drugs being rapidly adopted across geographies. The ageing global population is rapidly leading to geriatric cancer patients. For this group of patients, supportive care is critically important to augment survival and clinical outcomes. Providers of supportive care products are engaged in severe race to maintain their share and stronghold in the market, particularly with the steady advancement of life-extending cancer medications. However such treatment drugs are observed to be significantly expensive, particularly in the developing economies, where the reach of reimbursements still lags when compared to Western Europe and North America. This phenomenon will support the mainstay and further steady progress of cancer supportive drugs market in developing countries of Asia and Middle East and Africa. 

North America and Europe are the largest markets for cancer supportive care drugs. Huge population base and corresponding patient pool are the chief contributors to the dominance of Asia Pacific on the global front. It is anticipated that North America and Western Europe will witness moderate yet steady growth through the forecast period. The fastest market growth will be observed in Asia Pacific on the ground of significant population and corresponding patient pool, rising prevalence of cancer in the region and swift development of healthcare infrastructure. Government initiatives, growing commercialization of new supportive care drugs and rising adoption of direct-to-consumer marketing are predicted to be the key trends in the developed markets. Further clarity in reimbursement policies will open new opportunities for drug manufacturers in this market.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cancer Supportive Care market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Cancer Supportive Care market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Cancer Supportive Care market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Cancer Supportive Care market?
• Which is the largest regional market for Cancer Supportive Care market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Cancer Supportive Care market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Cancer Supportive Care market worldwide?